Browsing Tag
rare disease therapy
2 posts
What is HARLIKU and how will Cycle’s FDA-approved AKU drug help patients starting July 2025?
Cycle Pharmaceuticals secures FDA approval for HARLIKU™, the first approved treatment for alkaptonuria (AKU); launch in the U.S. expected July 2025.
Can SCENESSE become the first approved EPP treatment in Canada? Clinuvel files with Health Canada
Clinuvel Pharmaceuticals files for SCENESSE approval in Canada, aiming to bring the first-ever EPP treatment to patients. Find out how it could change lives.